Skip to main content

UPDATE — AP Biosciences to Present New Preclinical Data at American Association of Cancer Research Annual Meeting

Written by Customer Service on . Posted in Public Companies.

TAIPEI, Taiwan, April 21, 2025 (GLOBE NEWSWIRE) — AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through innovative bispecific antibodies, today announced that it will present a preclinical abstract in a poster presentation at the upcoming American Association for Cancer Research (AACR) Association Annual Meeting, taking place in Chicago, IL, April 25- 30, 2025. 

The data will showcase the potential of AP402, a first-in-class, next generation T cell engager targeting CD137 and p95HER2 in in-vivo and in vitro studies. AP402 recently received IND clearance to begin clinical trials in Australia this past February.

Details for the poster presentation are as follows:  

Title: AP402, a bispecific antibody targets p95HER2 and CD137, shows a potent antitumor activity
Poster Number: 6016
Presenter: Dr. Po-Lin Huang, Associate Director, Antibody Discovery
Session: Clinical Research, Therapeutic Antibodies, Including Engineered Antibodies 2
Location: Poster Section 35
Date and Time: 4/29/2025 2:00 – 5:00 PM

The poster will be made available on the AP Biosciences website following the session. 

About AP402

AP402 is a first-in-class bispecific antibody originated and developed by AP Biosciences to target p95HER2, a truncated variant of HER2 that is expressed in 30-40% of treatment-resistant HER2-positive cancers. AP402 combines p95HER2 binding with a CD137 activation domain to enable target-dependent T-cell activation exclusively within the tumor microenvironment. This design facilitates clustering of HER2 variants to effectively trigger CD137-mediated T-cell activation, while minimizing potential toxicity related to systemic cytokine release. The binding domains for p95HER2 and CD137 are designed to enhance bridging between HER2 variant-expressing cancer cells and CD137-expressing T-cells, ensuring efficient immune cell recruitment without spatial hindrance. This novel mechanism has positioned AP402 as a promising therapeutic approach to addressing tumors that have developed resistance to traditional anti-HER2 therapies, offering potential new hope for patients with refractory/recurrent cancers.

About AP Biosciences

AP Biosciences is a Taiwan-based clinical-stage biopharmaceutical company committed to developing innovative antibody-based therapies for cancer and other diseases. Applying its proprietary Omni-Mab and T-cube platforms, AP Biosciences is pioneering next generation bispecific antibodies that activate the immune system precisely where it’s needed, for both established and treatment-resistant cancers.

AP Biosciences Contact
Spike Lo
AP Biosciences
pr@apbioinc.com
+886-2-2653-2886

Media Contact
Jason Braco, PhD
LifeSci Communications
jbraco@lifescicomms.com
(908)-432-4243

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.